Regulation of fibroblast growth factor-23 in chronic kidney disease

被引:81
作者
Westerberg, Per-Anton
Linde, Torbjoern
Wikstroem, Bjoern
Ljunggren, Oesten
Stridsberg, Mats
Larsson, Tobias E.
机构
[1] Univ Uppsala Hosp, Dept Med Sci, S-75185 Uppsala, Sweden
[2] Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden
关键词
chronic kidney disease; fibroblast growth factor-23(FGF23); hyperphosphataemia; parathyroid hormone; phosphate;
D O I
10.1093/ndt/gfm347
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Fibroblast growth factor-23 (FGF23) is a circulating factor that regulates the renal reabsorption of inorganic phosphate (Pi) and is increased in chronic kidney disease (CKD). The aim of the current investigation was to study the regulation of FGF23 in CKD subjects with various degree of renal function. As such, we analysed the relationship between FGF23, Pi, calcium, parathyriod hormone (PTH), 25(OH) vitamin D-3(25(OH) D3), 1,25(OH) 2 vitamin D3(1,25( OH) D-2(3)) and estimated glomerular filtration rate (eGFR). Methods. Intact FGF23 and other biochemical variables were analysed in 72 consecutive adult outpatients with various stages of CKD ( eGFR ranging from 4-96 ml/min.) Association studies were performed using linear univariate and multivariate analysis. Results. FGF23 was significantly elevated at CKD stage 4 ( 266 +/- 315 pg/ml, P < 0.001) and 5 (702 +/- 489 pg/ml, P < 0.001) compared with CKD 1-2 (46 +/- 43 pg/ml). In CKD 4-5 an independent association between log FGF23 and Pi (P < 0.001), 25( OH) D3 (P < 0.05) as well as eGFR (P < 0.01) was observed. In contrast, in CKD 1-3 log PTH (P < 0.05) was the only independent predictor of log FGF23 in multivariate analysis. In CKD 1-5, Pi (P < 0.00001) and log PTH (P < 0.01) were explanatory variables for log FGF23 in multivariate analysis. Conclusions: We conclude that serum FGF23 increases in CKD 4-5, in parallel with the emerging hyperphosphataemia. Serum Pi is the most important predictor of FGF23 when GFR is less than 30 ml/min. In contrast, our data suggest that Pi may not be an important determinant of FGF23 in normophosphataemic CKD subjects. Finally, the association between FGF23 and PTH in CKD may suggest a co-regulation that remains to be further elucidated.
引用
收藏
页码:3202 / 3207
页数:6
相关论文
共 19 条
[1]   Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men [J].
Antoniucci, Diana M. ;
Yamashita, Takeyoshi ;
Portale, Anthony A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (08) :3144-3149
[2]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[3]   Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women [J].
Burnett, Sherri-Ann M. ;
Gunawardene, Samantha C. ;
Bringhurst, F. Richard ;
Juppner, Harald ;
Lee, Hang ;
Finkelstein, Joel S. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (08) :1187-1196
[4]   Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men [J].
Burnett-Bowie, Sherri-Ann M. ;
Mendoza, Natalia ;
Leder, Benjamin Z. .
BONE, 2007, 40 (04) :913-918
[5]   Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men [J].
Ferrari, SL ;
Bonjour, JP ;
Rizzoli, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1519-1524
[6]   Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease [J].
Gutierrez, O ;
Isakova, T ;
Rhee, E ;
Shah, A ;
Holmes, J ;
Collerone, G ;
Jüppner, H ;
Wolf, M .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2205-2215
[7]   FGF-23 in patients with end-stage renal disease on hemodialysis [J].
Imanishi, Y ;
Inaba, M ;
Nakatsuka, K ;
Nagasue, K ;
Okuno, S ;
Yoshihara, A ;
Miura, M ;
Miyauchi, A ;
Kobayashi, K ;
Miki, T ;
Shoji, T ;
Ishimura, E ;
Nishizawa, Y .
KIDNEY INTERNATIONAL, 2004, 65 (05) :1943-1946
[8]   Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. [J].
Jonsson, KB ;
Zahradnik, R ;
Larsson, T ;
White, KE ;
Sugimoto, T ;
Imanishi, Y ;
Yamamoto, T ;
Hampson, G ;
Koshiyama, H ;
Ljunggren, Ö ;
Oba, K ;
Yang, IM ;
Miyauchi, A ;
Econs, MJ ;
Lavigne, J ;
Jüppner, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1656-1663
[9]   A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis [J].
Larsson, T ;
Yu, XJ ;
Davis, SI ;
Draman, MS ;
Mooney, SD ;
Cullen, MJ ;
White, KE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :2424-2427
[10]   Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers [J].
Larsson, T ;
Nisbeth, U ;
Ljunggren, Ö ;
Jüppner, H ;
Jonsson, KB .
KIDNEY INTERNATIONAL, 2003, 64 (06) :2272-2279